S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.15%) $0.928
USD/NOK
(0.13%) $10.86
USD/GBP
(0.01%) $0.792
USD/RUB
(-0.07%) $92.51

Realtime updates for Zentalis Pharmaceuticals [ZNTL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
83.33%
return 6.21%
SELL
40.00%
return 5.09%
Last Updated28 Mar 2024 @ 16:00

3.75% $ 15.76

SELL 63070 min ago

@ $11.35

Issued: 14 Feb 2024 @ 09:30


Return: 38.85%


Previous signal: Feb 13 - 09:30


Previous signal: Buy


Return: 3.37 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers...

Stats
Today's Volume 579 811
Average Volume 823 732
Market Cap 1.12B
EPS $0 ( 2024-03-06 )
Next earnings date ( $-0.850 ) 2024-05-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -3.53
ATR14 $0.0210 (0.13%)
Insider Trading
Date Person Action Amount type
2024-02-12 Epperly Melissa B, Sell 2 573 Common Stock
2024-02-12 Gallagher Cam Sell 1 173 Common Stock
2024-02-01 Hausman Diana Buy 337 500 Common Stock
2024-02-01 Hausman Diana Buy 337 500 Stock Option (Right to Buy)
2024-02-01 Lackner Mark Buy 141 000 Common Stock
INSIDER POWER
87.25
Last 96 transactions
Buy: 10 141 496 | Sell: 672 173

Volume Correlation

Long: -0.31 (neutral)
Short: -0.98 (very strong negative)
Signal:(25.188) Possible Trading Opportunity Present (swing)

Zentalis Pharmaceuticals Correlation

10 Most Positive Correlations
10 Most Negative Correlations
RAVN-0.813

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Zentalis Pharmaceuticals Correlation - Currency/Commodity

The country flag 0.06
( neutral )
The country flag -0.09
( neutral )
The country flag 0.00
( neutral )
The country flag 0.25
( neutral )
The country flag -0.37
( neutral )
The country flag 0.36
( neutral )

Zentalis Pharmaceuticals Financials

Annual 2023
Revenue: $0
Gross Profit: $-1.39M (0.00 %)
EPS: $-4.47
Q4 2023
Revenue: $0
Gross Profit: $-337 000 (0.00 %)
EPS: $-0.860
Q3 2023
Revenue: $0
Gross Profit: $-348 000 (0.00 %)
EPS: $-0.790
Q2 2023
Revenue: $0
Gross Profit: $-344 000 (0.00 %)
EPS: $-1.850

Financial Reports:

No articles found.

Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators